Skip to main content
    V

    Vivos Therapeutics Inc (VVOS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.08
    -0.00 (-3.04%)

    Market Cap: $3.29M

    Last updated: Nov 17, 2026 at 4:14 PM ET

    Vivos Therapeutics Inc (VVOS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Vivos Therapeutics (VVOS) has a market cap of $3.29M and an enterprise value of $8.06M. Its share count is up 141.97% from a year earlier. It kept -108.11% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 144.70% above the market cap, as debt exceeds cash.

    Market Cap$3.29M
    Enterprise Value$8.06M
    Latest price (Nov 17, 2026)$0.08

    Key Dates

    The next earnings report is expected on Apr 13, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateApr 13, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 50.03% in the quarter ended Sep 30, 2026 and grew 100.25% a year over 2 years.

    Shares Outstanding26.53M
    Shares Change (YoY)+141.97%
    Shares Change (QoQ)+50.03%
    Share Count Growth (2Y CAGR)+100.25%

    Valuation Ratios

    Sales and book value multiples are 0.1x and 0.9x.

    P/S Ratio0.1x
    Forward P/S0.2x
    P/B Ratio0.9x

    Price Statistics

    The stock is down 96.59% over 52 weeks and trades 42.86% below its 50-day average.

    Beta (1Y)1.63
    52-Week Change-96.59%
    1-Month Change-40.92%
    3-Month Change-71.09%
    6-Month Change-86.38%
    5-Year Change-99.87%
    Total Return (1Y)-96.59%
    Total Return (3Y CAGR)-72.97%
    Total Return (5Y CAGR)-74.49%
    Max Drawdown (1Y)-96.85%
    Max Drawdown (3Y)-99.81%
    Sharpe Ratio (1Y)-3.48
    Correlation with SPY (1Y)0.23
    50-Day Average$0.14
    200-Day Average$0.64
    52-Week Range$0.07 to $2.69
    RSI (14 Days)26.0
    Average Volume (20 Days)1.22M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.22x current liabilities, and total debt is 2.12x shareholder equity.

    Current Ratio0.22x
    Quick Ratio0.22x
    Debt / Equity2.12x

    Returns and Efficiency

    Return on invested capital is -237.85% and return on equity is -940.59% over the last 12 months.

    Return on Equity (ROE)-940.59%
    Return on Assets (ROA)-97.12%
    Return on Invested Capital (ROIC)-237.85%
    Return on Capital Employed (ROCE)-331.66%
    Asset Turnover0.85x
    Receivables Turnover10.78x

    Scores

    VVOS has an Altman Z-Score of -11.51, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-11.51
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $20.53M over the last 12 months is up 18.57% from the 12 months before.

    Revenue$20.53M
    Revenue Growth (YoY)+18.57%
    Gross Profit$12.31M
    Operating Income-$21.71M
    Pretax Income-$22.20M
    Net Income-$22.20M
    EBITDA-$20.24M
    EBIT-$22.20M
    Reported EPS (TTM)-$1.48

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 10.32% of the $22.86M in total assets.

    Cash and Equivalents$247.00K
    Total Debt$5.01M
    Net Debt$4.77M
    Net Debt Per Share$0.18
    Working Capital-$12.65M
    Shareholder Equity$2.36M
    Book Value Per Share$0.09
    Tangible Book Value-$9.65M
    Total Assets$22.86M
    Total Liabilities$20.69M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $7.21M of capital spending, operating cash flow left -$23.36M of free cash flow.

    Operating Cash Flow-$16.15M
    Capital Expenditures$7.21M
    Free Cash Flow-$23.36M
    FCF Per Share-$0.69
    Depreciation and Amortization$1.96M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -105.75%.

    Gross Margin59.96%
    Operating Margin-105.75%
    Pretax Margin-108.11%
    Net Margin-108.11%
    EBITDA Margin-98.58%
    EBIT Margin-108.11%
    FCF Margin-113.76%
    Gross Margin (5Y Average)63.51%

    Growth

    Revenue grew 2.87% a year over 3 years.

    Revenue Growth (3Y CAGR)+2.87%
    Revenue Growth (5Y CAGR)-7.77%

    Revenue and profit by year

    Dividends and Yields

    VVOS does not pay a dividend. Its free cash flow yield is -1104.71%.

    FCF Yield-1104.71%
    Buyback Yield-204.51%
    Shareholder Yield-204.51%

    Stock Splits

    The last split was a 1-for-25 reverse split on Oct 27, 2023.

    Last Split DateOct 27, 2023
    Split TypeReverse split
    Split Ratio1:25

    Peer Position

    Against 6 similar companies, VVOS has the lowest P/S and the 6th highest ROIC.

    P/S Ratio0.1x vs 0.6x median
    ROIC-237.85% vs -65.64% median
    Revenue Growth (Trailing 4 Quarters, YoY)+18.57% vs +36.55% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 39.79% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+39.79%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About VVOS

    What is VVOS's market cap?

    Vivos Therapeutics has a market cap of $3.29M. Its enterprise value, which adds debt and subtracts cash, is $8.06M.

    How many shares of VVOS are outstanding?

    Vivos Therapeutics has 26.53M shares outstanding. The count is up 141.97% from a year earlier.

    Does VVOS pay a dividend?

    No. Vivos Therapeutics does not pay a dividend.

    How much debt does VVOS have?

    Vivos Therapeutics has $5.01M of total debt and $247.00K of cash and equivalents, a net debt position of $4.77M.